EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer

Niranjan Meher, Henry F VanBrocklin, David M Wilson, Robert R Flavell iD

Pharmaceuticals · 17.02.2023 · 16 (2) · 315

DOI: 10.3390/ph16020315 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 17.02.2023. Verfasst von Niranjan Meher und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94143, USA. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Health (NIH), NCI NIH HHS, Cancer Center Support Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted nanotheranostic systems offer significant benefits due to the integration of diagnostic and therapeutic functionality, promoting personalized medicine. In recent years, prostate-specific membrane antigen (PSMA) has emerged as an ideal theranostic target, fueling multiple new drug approvals and changing the standard of care in prostate cancer (PCa). PSMA-targeted nanosystems such as self-assembled nanoparticles (NPs), liposomal structures, water-soluble polymers, dendrimers, and other macromolecules are under development for PCa theranostics due to their multifunctional sensing and therapeutic capabilities. Herein, we discuss the significance and up-to-date development of “PSMA-targeted nanocarrier systems for radioligand imaging and therapy of PCa”. The review also highlights critical parameters for designing nanostructured radiopharmaceuticals for PCa, including radionuclides and their chelators, PSMA-targeting ligands, and the EPR effect. Finally, prospects and potential for clinical translation is discussed.

Schlagwörter

Stichwörter der Autor:innen

enhanced permeability and retention (EPR) effectnanocarriersnanoparticlepositron emission tomography (PET)prostate cancer theranosticsprostate-specific membrane antigen (PSMA)radioligand theranosticsradiopharmaceutical therapysmall-molecule PSMA inhibitors

Autor:innen und Institutionen

  • Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA 94143, USA .
  • Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA 94143, USA.
  • Department of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158, USA.

ORCID-Profile: Robert R Flavell

Förderung

  • National Institute of Health (NIH)
  • NCI NIH HHS
  • Cancer Center Support Grant
  • US Department of Defense
  • Cancer Center
  • US Department of Defense Translational Science Award
  • NIH National Cancer Institute
  • Cancer League (RRF)

Zitieren

APA

Meher, N., VanBrocklin, H. F., Wilson, D. M., & Flavell, R. R. (2023). PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer. Pharmaceuticals, 16(2), 315. https://doi.org/10.3390/ph16020315

Vancouver

Meher N, VanBrocklin HF, Wilson DM, Flavell RR. PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer. Pharmaceuticals. 2023;16(2):315. doi:10.3390/ph16020315

BibTeX
@article{Meher2023,
  author = {Meher, Niranjan and VanBrocklin, Henry F and Wilson, David M and Flavell, Robert R},
  title = {PSMA-Targeted Nanotheranostics for Imaging and Radiotherapy of Prostate Cancer},
  journal = {Pharmaceuticals},
  year = {2023},
  volume = {16},
  number = {2},
  pages = {315},
  doi = {10.3390/ph16020315}
}
Kostenlos starten →